

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Confirmation No. : 2241

Appln. No. : 10/734,930
Applicant : Evan B. Dreyer
Filed : 12/12/2003
TC/AU : 1612
Examiner : Zohreh A. Fay
Docket No. : 17322CON2CIP(AP) (1957205-00126)
Customer No. : 51957
Title : Calcium Blockers to Treat Proliferative Retinal Diseases

AMENDMENT TRANSMITTAL LETTER (Large Entity)

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Amendment to the Office Action dated August 6, 2008 on the above-identified application.

[X] Amendment (10 pages)

[X] The fee has been calculated as shown below.

CLAIMS	COLUMN A <i>Claims Remaining After Amendment</i>	COLUMN B <i>Highest Number Previously Paid</i>	COLUMN C <i>Present Extra</i>	<i>Rate</i>	<i>Additional Fee</i>
Total	13	20	0	x \$50	\$.00
Independent	2	3	0	x \$210	\$.00
[] First Presentation of Multiple Dep. Claim x \$280 =					\$.00
Time Extension Fees:					\$.00
Total Due:					\$.00

Please charge Deposit Account 01-0885 for any fees related to this Amendment.

Respectfully submitted,

John E. Wurst/

John E. Wurst
Reg. No. 40,283
Attorney of Record

Date: November 6, 2008

Please send all inquiries to:
John E. Wurst (T2-7H)
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714/246-5475/Facsimile: 714/246-4249